CLL-1 CAR-T cell therapy for relapsed or refractory leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental CAR-T cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. It uses a special marker on leukemia cells (CLL-1) to target and kill them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia called acute myeloid leukemia (AML) that has either returned or has not improved after standard treatment (relapsed or refractory).
- Your leukemia cells must show a specific marker called CLL-1 in at least half of them (found through blood or bone marrow tests).
- You must be between 18 and 75 years old and be well enough to carry out daily activities (performance status 0-2).
- Your organ function (kidneys, liver, heart, lungs) must be adequate.
- You must agree to use effective contraception for at least 12 months after treatment if you are of reproductive age.
- You must not have had certain prior treatments like gene therapy or CAR-T therapy, and no active severe infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational therapy (CT1390B) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the therapy is safe and helps patients with a specific marker called CLL-1.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.